Proteomics International Laboratories (ASX: PIQ) has unveiled new results for its PromarkerEso blood test, a patented, first-in-class diagnostic that delivers a simple and scalable pathway for early detection. With clinical validation showing high accuracy in identifying early-stage EAC, PromarkerEso may well change the standard of care in managing this difficult disease. With patents already granted in Europe, China, and Australia—and other territories pending.